Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
  • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
  • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/42—Amides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
  • A61K8/608—Derivatives containing from 2 to 10 oxyalkylene groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/73—Polysaccharides
  • A61K8/738—Cyclodextrins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
  • A61K8/86—Polyethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
  • A61K8/89—Polysiloxanes
  • A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations

Definitions

• the present invention relates to an external preparation composition for preventing or treating symptoms or diseases related to dermatopathy caused by dryness, UV rays and aging such as wrinkles and sags of the skin, pigmentation of the skin, skin roughness and coarse texture and skin diseases such as psoriasis, lichen, ichthyosis, keratosis, Darier's disease, pustulosis, acne, eczema and atopic dermatitis.
• symptoms or diseases related to dermatopathy caused by dryness, UV rays and aging such as wrinkles and sags of the skin, pigmentation of the skin, skin roughness and coarse texture and skin diseases such as psoriasis, lichen, ichthyosis, keratosis, Darier's disease, pustulosis, acne, eczema and atopic dermatitis.
• a normal skin looks flat at a glance, but a skin surface has a pattern constituted of fine grooves (sulci cutis) and parts (cristae cutis) surrounded by them, that is, a “texture”.
• the texture is also given as an important factor taking part in the beauty of the skin, and disturbance and a coarseness change in the texture are a large factor for damaging the beauty of the skin.
• sulci cutis provide a corneum having low flexibility with capability to meet dynamic deformation, and they are a passage for sebum and sweat. Accordingly, the skin can maintain smoothness, gloss and flexibility by spreading a lot of the sulci cutis [J. Soc. Cosmet. Chem. Japan, 27 (3), 1993 and The Nishinihon J. of Derm. 63 (2), 103, 2001].
• skin diseases such as pustulosis, acne, eczema, psoriasis, lichen, ichthyosis, keratosis and atopic dermatitis bring about a serious change in the appearance and the function of the skin.
• Vitamins A, C, D and derivatives thereof and urea are widely known as the above medicines.
• substances having an epithelium-abrasive action such as ⁇ -hydroxy acids including lactic acid and glycolic acid and ⁇ -hydroxy acids represented by salicylic acid.
• carbohydrate derivatives shown in, for example, Japanese translation of PCT international publication for patent application No. 501940/1999) are known as a medicine provided with an epithelium-abrasive action by inhibiting a corneum binding action.
• amino acids, polyhydric alcohols, polysaccharides, lipids such as ceramides and various ingredients extracted from natural products are blended with skin external preparations as a conventional skin roughness-improving agent for the purpose of providing a moisture holding effect.
• ellagic acid, kojic acid, arbutin, hydroquinone and various ingredients extracted from natural products have been compounded with conventional whitening agents.
• medicines and cosmetic compositions blended with the conventional drug efficacy components described above do not still have satisfactory effects on a change in the skin, and the existing situation is that medicines having excellent effects are desired to be developed.
• retinoids including retinoic acid have various and strong physiologic action such as controlling of proliferation and differentiation of cells and controlling of gene expression. It is reported by researches which have so far been made that retinoids have excellent effects for preventing or treating symptoms or diseases related to dermatopathy caused by dryness, UV rays and aging such as wrinkles, sags and pigmentation of the skin and skin diseases such as psoriasis, lichen, ichthyosis, keratosis, Darier's disease, pustulosis, acne, eczema and atopic dermatitis.
• retinoids have so far been extremely limited in application to cosmetics and medicines.
• the present invention intends to solve them, and an object thereof is to provide an external preparation composition for preventing or treating symptoms or diseases related to dermatopathy caused by dryness, UV rays, active oxygen and aging such as wrinkles and sags of the skin, pigmentation of the skin, skin roughness and coarse texture, dyskeratosis such as psoriasis, lichen, ichthyosis and Darier's disease and skin diseases such as pustulosis, acne, eczema and atopic dermatitis.
• Another object of the present invention is to provide an external preparation composition which is useful as at least one of a wrinkle-improving agent, a coarse texture-improving agent, a skin roughness-improving agent, a whitening agent and a acne-improving agent.
• a specific acyl glucosamine derivative does not have side effects such as irritation and teratogenesis and that it has an excellent effect for dermatopathy and diseases such as wrinkles and sags of the skin, pigmentation of the skin, skin roughness and coarse texture, baldness, psoriasis, lichen, ichthyosis, keratosis, pustulosis, acne, eczema and atopic dermatitis.
• the present invention comprises the following items (0.1) to (5).
• An external preparation composition comprising at least one of acyl glucosamine derivatives represented by the following Formula (I): wherein R 1 , R 2 , R 3 and R 4 represent a hydrogen atom, a saturated or unsaturated, linear or branched fatty acid residue having 2 to 36 carbon atoms or a linear or branched alkyl group having 1 to 4 carbon atoms which may have a hydroxyl group, and they may be the same or different each other; R 5 represents a hydrogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms which may have a hydroxyl group; X is any one of groups represented by the following Formulas (A) to (C): wherein Y in the formulas (A) and (B) described above represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms in which an ether group may be interposed between a bond; and n represents an integer of 0 to 10; and R 6 represents a linear or branched alkyl
• the external preparation composition of the present invention is characterized by comprising at least one of acyl glucosamine derivatives represented by the following Formula (I): wherein R 1 , R 2 , R 3 and R 4 represent a hydrogen atom, a saturated or unsaturated, linear or branched fatty acid residue having 2 to 36 carbon atoms or a linear or branched alkyl group having 1 to 4 carbon atoms which may have a hydroxyl group, and they may be the same or different each other; R 5 represents a hydrogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms which may have a hydroxyl group; X is any one of groups represented by the following Formulas (A) to (C): wherein Y in the formulas (A) and (B) described above represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms in which an ether group may be interposed between a bond; and n represents an integer of 0 to 10; and R 6 represents a
• the acyl glucosamine derivatives represented by Formula (I) include, for example, N-retinoyl-D-glucosamine, 1,3,4,6-tetra-O-acetyl-N-retinoyl-D-glucosamine, N-retinoyl-6-O-retinoyl-D-glucosamine, N-lauroyl-D-glucosamine, N-myristoyl-D-glucosamine, N-tetradecenoyl-D-glucosamine, N-palmitoyl-D-glucosamine, N-hexadecenoyl-D-glucosamine, N-stearoyl-D-glucosamine, N-isostearoyl-D-glucosamine, N-oleoyl-D-glucosamine, N-linoleoyl-D-glucosamine, N-linolenoyl-D-glucosamine, N-
• R 1 to R 5 are hydrogen atoms and that R 6 may have a substituent and has 11 to 36 carbon atoms, and preferred are, for example, N-retinoyl-D-glucosamine, N-lauroyl-D-glucosamine, N-myristoyl-D-glucosamine, N-tetradecenoyl-D-glucosamine, N-palmitoyl-D-glucosamine, N-hexadecenoyl-D-glucosamine, N-stearoyl-D-glucosamine, N-isostearoyl-D-glucosamine, N-oleoyl-D-glucosamine, N-linoleoyl-D-glucosamine, N-linolenoyl-D-glucosamine, N-eicosenoyl-D-glucosamine, N-eicosadienoy
• N-retinoyl-D-glucosamine N-lauroyl-D-glucosamine, N-myristoyl-D-glucosamine, N-palmitoyl-D-glucosamine, N-stearoyl-D-glucosamine, N-isostearoyl-D-glucosamine, N-tetradecenoyl-D-glucosamine, N-hexadecenoyl-D-glucosamine, N-oleoyl-D-glucosamine, N-linoleoyl-D-glucosamine, N-linolenoyl-D-glucosamine, N-eicosenoyl-D-glucosamine, N-eicosadienoyl-D-glucosamine, N-eicosatrienoyl-D-glucosamine, N-eicosapentaenoyl-D-glucosamine, N-retino
• acyl glucosamine derivatives described above which are used in the present invention can be obtained by conventional methods, and they can be synthesized on conditions described in, for example, J. Am. Chem. Soc., 78, 2825 (1956).
• the various acyl glucosamine derivatives represented by Formula (I) described above can be used in a single kind (each alone) or in suited combination of two or more kinds thereof.
• acyl glucosamine derivatives in the present invention can suitably be used for an external preparation composition.
• a content of the whole substances described above is preferably 0.0001 to 10% by mass (hereinafter referred to merely as “%”), particularly preferably 0.001 to 5% based on the total amount of the external preparation composition.
• the effects of the present invention are less likely to be sufficiently exhibited. On the other hand, if the content exceeds 10%, further improvement in the effects can not be observed.
• R 6 in the acyl glucosamine derivative represented by Formula (I) described above is retinoid
• a solubility thereof in the preparation is improved if the cis type stereoisomer is contained in a proportion of 0.5% or more based on the trans type.
• the above cis type stereoisomer includes, for example, at least one of 7-cis, 9-cis, 11-cis, 13-cis, 7,9-di-cis, 9,13-di-cis, 11,13-di-cis and 7,9,13-tri-cis.
• R 6 in the acyl glucosamine derivative represented by Formula (I) described above is retinoid
• at least one of the cis type stereoisomers described above is preferably contained in a proportion of 0.5% or more based on the trans type from the viewpoint of further increase in the solubility.
• the external preparation composition of the present invention further comprises a percutaneous absorption accelerator and/or a chemically active substance having a skin care effect, whereby the effects of the present invention can further be improved.
• the percutaneous absorption accelerator which can be used in the present invention shall not specifically be restricted as long as it is usually blended with skin external preparations (medicines, quasidrugs and cosmetics).
• the percutaneous absorption accelerator which can be used specifically includes, for example, (1) ester oils having high affinity to the skin, for example, isopropyl palmitate, isopropyl myristate, diisopropyl adipate, dioctyl succinate and octyldodecyl lactate, (2) fatty acids or esters thereof having a double bond which positively acts on a structure of intercellular lipid, for example, oleic acid, ethyl oleate, decyl oleate, oleyl oleate, octyldodecyl oleate and propylene glycol oleate, (3) substances having protein denaturation action which acts on keratin protein, for example, urea and derivatives thereof, glycolic acid and salts thereof, lactic acid and salts thereof and salicylic acid, (4) substances which change a distribution ratio of effective ingredients onto the skin, for example, alcohols (ethanol and isopropanol) and
• the preferred percutaneous absorption accelerators are isopropyl palmitate, oleic acid and derivatives thereof, urea and derivatives thereof, glycolic acid and derivatives thereof, salicylic acid and derivatives thereof, ethanol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, polyethylene glycol and creatinine.
• a content of the above percutaneous absorption accelerators varies depending on the kind of the percutaneous absorption accelerators and the type of the preparation, and it is preferably 0.01 to 15%, more preferably 0.1 to 10% based on the total amount of the external preparation composition.
• a content of the above percutaneous absorption accelerator is less than 0.01%, the effects of the present invention are not exerted further more. On the other hand, if the above accelerator is added in excess of 15%, the effects of the present invention are not so different, and the stability of the skin cosmetic is inhibited in a certain case.
• the chemically active substance having a skin care effect which can be used in the present invention includes various kinds of conventionally known compounds, for example, drug efficacy substances and physiologically active substances.
• the above drug efficacy substances and/or physiologically active substances include substances revealing effects such as whitening, improving wrinkles, accelerating blood circulation, controlling sebum, preventing acnes, preventing skin roughness and anti-inflammation.
• the whitening substance includes, for example, retinoic acid, ellagic acid, hydroquinone and derivatives thereof, kojic acid, L-ascorbic acid and derivatives thereof, placenta extracts and 4-n-butylresorcinol, and ellagic acid, arbutin, kojic acid and water-soluble placenta extracts are particularly preferred.
• the wrinkle-improving substance includes, for example, pantothenic acid, pantothenic acid derivatives and salts thereof, coenzyme A, oxidizing Coenzyme A and salts thereof, retinoic acid, vitamin A, vitamin A derivatives and salts thereof, marine algae extracts excluding brown algae, hyaluronic acid and salts thereof, an NMF component, amino acid and amino acid derivatives and ⁇ -hydroxy acid.
• the sebum-controlling substance includes, for example, oil-soluble Licorice extracts, Cumaceba extracts, Siam rosewood extracts, Blue mallow extracts, Swertia herb extracts, Maackia amurensis extracts, vitamin A, vitamin A derivatives and retinoic acid.
• the anti-inflammatory substance and the skin roughness-preventing substance include, for example, allantoin, glycyrrhetic acid and derivatives thereof, glycyrrhizic acid and derivatives thereof, urea, lysozyme chloride, guaiazulene and ⁇ -oryzanol.
• the acne-preventing-improving substance includes, for example, salicylic acid, pyrocton olamin, vitamin A derivatives thereof, retinoic acid, photosensitizers, oil-soluble Licorice extracts, Cumaceba extracts, Siam rosewood extracts and Blue mallow extracts.
• a content of the above chemically active substances having a skin care effect varies depending on the components selected, and in the case of the external preparations of emulsified and solubilized systems, it is, as a standard, preferably 0.001 to 20%, more preferably 0.05 to 10% based on the total amount of the external preparation composition.
• the following silicone oils and silicone derivatives are efficiently used as a surfactant, a gelatinizing agent and a base agent, whereby the preparation which has less skin irritation and which is expected further effects can be obtained.
• the silicone oils which can be used may be any of a linear type and a cyclic type and can be used regardless of a molecular weight. Also, they may be volatile or non-volatile. Further, they may be of a low viscosity or may be a wax, and they shall not specifically be restricted in elasticity and can be used according to the targeted preparation forms.
• the silicone derivatives which can be used include a polyoxyalkylene-added type and an organopolysiloxane type. They include, for example, polyoxyalkylene-modified silicone, polyoxyalkylene-modified organopolysiloxane, polyoxyalkylene alkyl-co-modified organopolysiloxane and elastomer solid organopolysiloxane.
• the polymer parts may be cross-linked, and they may be any of a wholly cross-linked type and a partially cross-linked type. Further, they may be copolymers such as alkyl methicone copolyols and alkyl dimethicone copolyols.
• silicone oils and silicone derivatives may be used alone or in combination of a plurality thereof.
• the total content of the above silicone oil and silicone derivative varies depending on the kind thereof and the type of the preparation, and it is preferably 3 to 50%, more preferably 5 to 30% based on the total amount of the external preparation composition.
• the external preparation composition of the present invention can suitably be used in the fields of cosmetics, medicines and quasidrugs, and in particular, it can suitably be used as at least one of a wrinkle-improving agent, a coarse texture-improving agent, a skin roughness-improving agent, a whitening agent and a acne-improving agent.
• the acyl glucosamine derivative described above can further contain in suited amounts other components usually used for external preparations such as cosmetics and quasidrugs, for example, a moisture holding agent, alcohol, a thickener, an antioxidant, a pH-controlling agent, an antiseptic agent, a perfume, a pigment, a whitening agent, a UV absorber, a UV-scattering agent, vitamins and amino acids as well as an oil component, water and a surfactant in addition to the percutaneous absorption accelerator and/or the chemically active substance having a skin care effect, the silicone oil and the silicone derivative which are preferably added, as long as the effects of the present invention are not damaged.
• other components usually used for external preparations such as cosmetics and quasidrugs, for example, a moisture holding agent, alcohol, a thickener, an antioxidant, a pH-controlling agent, an antiseptic agent, a perfume, a pigment, a whitening agent, a UV absorber, a UV-scattering agent, vitamins and amino
• a skin irritative score after application for 3 days straight was evaluated according to the following evaluation criteria (Draize method). The above irritative score was shown by the total points (full marks: 8 points) of erythema and edema.
• Solubility of the acyl glucosamine derivatives shown in the following Table 2 in the ethanol/propylene glycol (7:3) solvent was prescribed according to evaluation criteria (Japanese Pharmacopoeia) by a degree at which the above pulverized derivative was dissolved in the solvent at 20° C. within 30 minutes when it was strongly shaken every 5 minutes for 30 seconds.
• Evaluation Criteria of Solubility Evaluation point: Amount of the solvent required for dissolving 1 g or 1 ml of the solute ⁇ : freely soluble 1 ml or more and less than 10 ml ⁇ : soluble 10 ml or more and less than 100 ml ⁇ : slightly soluble 100 ml or more and less than 1000 ml X: very slightly soluble 1000 ml or more and less than 10000 ml
• acyl glucosamine derivative is a retinoyl glucosamine derivative
• a retinoyl glucosamine derivative in which a cis type stereoisomer accounts for 0.5% has excellent solubility than that of a retinoyl glucosamine derivative in which a trans type stereoisomer accounts for 100%.
• mice per 1 group were irradiated on the back skin once a day with UVB at 50 mJ/cm 2 five times a week over a period of 10 weeks. After finishing irradiation, each 100 ⁇ L of an ethanol/propylene glycol (7:3) solution containing 0.05% of various acyl glucosamine derivatives shown in the following Table 3 was applied on the mouse back in a frequency of once a day and five times a week over 8 weeks.
• Evaluation point 0 a lot of fine striations is present on the back and the flank; fine striations run in a direction from the head to the tail; and the striations appear or disappear with the motion of the mouse.
• mice per 1 group were irradiated on the back skin once a day with UVB at 40 mJ/cm 2 three times a week over a period of 6 weeks. After finishing irradiation, each 100 ⁇ L of an ethanol/propylene glycol (7:3) solution containing 0.05% of various acyl glucosamine derivatives shown in the following Table 4 or an ethanol/propylene glycol (7:3) solution was applied on the mouse back in a frequency of once a day and five times a week over 4 weeks.
• a replica agent brand name SILFLO; manufactured by UK FLEXICO DEVELOPMENTS LTD.
• a replica of a UV-non-irradiated group (4 heads) was obtained as a control in the same manner.
• the coarseness of the texture was defined by a “number of texture intersection point”, wherein a point in which three or more sulci cutis are joined is counted as one intersection point, and the number of the texture intersection points present in a square of 1 cm ⁇ 1 cm was counted on the replica photograph.
• a 10% SDS solution was used to artificially form a skin roughness in the inside of a forearm of a human being, and a hydrophilic ointment blended with 0.05% of various acyl glucosamine derivatives shown in the following Table 5 was applied thereon twice a day.
• the skin roughness-improving degree observed 3 days later after application was evaluated using a change in a stratum corneum water content as an index.
• the stratum corneum water content is measured in terms of a conductance ( ⁇ S).
• the improving degree was shown by a relative value, wherein the conductance observed when applying the hydrophilic ointment blended with no acyl glucosamine derivative was set at 100, and the skin roughness-improving rate was calculated according to the following equation (IV).
• the evaluation results thereof are shown in the following Table 5.
• composition of essence for acne Acyl glucosamine derivative 0.05% POE(40)-hardened castor oil 0.5 Carboxyvinyl polymer (molecular weight: 0.2 1,000,000 to 1,500,000) Xanthan gum 0.2 1,3-Butylene glycol 8.0 Ethanol 10.0 Sodium citrate 0.3 Methyl paraben 0.1 Rose water 0.5 Triisopropanolamine 0.1 Perfume trace amount Purified water balance Total 100.0
• Back body hair of color guinea pigs were shaved by means of a hair clipper and a shaver, and they were irradiated with UV rays once a day, 4 times a week and 8 times in total, whereby 4 parts of pigmentation having an area of about 2.25 cm 2 were formed on the backs of the respective guinea pigs.
• the acyl glucosamine derivatives of the present invention have less skin irritation as the external preparation compositions and are excellent in a wrinkle-improving effect, a coarse texture-improving effect, a skin roughness-improving effect, a acne-improving effect and a whitening effect.
• the external preparation composition containing at least one of the acyl glucosamine derivatives of the present invention represented by Formula (I) described above is useful as a wrinkle-improving agent, a coarse texture-improving agent, a skin roughness-improving agent, a whitening agent and a acne-improving agent.
• blend compositions are shown in the following Tables 8 to 15 with respect to various uses (lotion, cosmetic gel, cosmetic milky lotion, cosmetic cream, ointment and silicone oil and silicone derivative base-containing cream) and efficacy (wrinkle-improving, coarse texture-improving, skin roughness-improving, whitening and acne-improving) of the external preparation compositions containing the acyl glucosamine derivatives having the respective improving effects described above.
• the respective lotions (for antiwrinkle, texture-improving, skin roughness, acne and whitening) were prepared according to blend compositions shown in the following Table 8.
• the respective cosmetic gels (for antiwrinkle, texture-improving, skin roughness, acne and whitening) were prepared according to blend compositions shown in the following Table 9.
• the respective cosmetic milky lotions (for antiwrinkle, texture-improving, skin roughness, acne and whitening) were prepared according to blend compositions shown in the following Table 10 and Table 11.
• the respective cosmetic creams (for antiwrinkle, texture-improving, skin roughness, acne and whitening) were prepared according to blend compositions shown in the following Table 12 and Table 13.
• the respective ointments (for antiwrinkle, texture-improving, skin roughness, acne and whitening) were prepared according to blend compositions shown in the following Table 14.
• Creams for antiwrinkle, acne/whitening and texture-improving/skin roughness
• silicone oils and silicone derivatives base were prepared according to blend compositions shown in the following Table 15.
• a silicone mixture A shown in the following Table 15 is a paste-like polyether-modified silicone composition obtained by subjecting cross-linking type polyether-modified silicone and methyl polysiloxane to kneading treatment under a shearing force, and a ratio of cross-linking type polyether-modified silicone to methyl polysiloxane in the composition is 1:0.1 to 10:1.
• the external preparation composition of the present invention can suitably be used for preventing or treating symptoms or diseases related to dermatopathy caused by dryness, UV rays, active oxygen and aging such as wrinkles and sags of the skin, pigmentation of the skin, skin roughness and coarse texture, dyskeratosis such as psoriasis, lichen, ichthyosis, keratosis and Darier's disease and skin diseases such as pustulosis, acne, eczema and atopic dermatitis.
• symptoms or diseases related to dermatopathy caused by dryness, UV rays, active oxygen and aging such as wrinkles and sags of the skin, pigmentation of the skin, skin roughness and coarse texture, dyskeratosis such as psoriasis, lichen, ichthyosis, keratosis and Darier's disease and skin diseases such as pustulosis, acne, eczema and atopic dermatitis.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Emergency Medicine (AREA)
• Dermatology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Priority Applications (2)

Applications Claiming Priority (1)

Related Parent Applications (1)

Related Child Applications (2)

Publications (1)

Family

ID=30795860

Family Applications (3)

Family Applications After (2)

Country Status (6)

Cited By (12)

Families Citing this family (10)

Citations (3)

Family Cites Families (16)

• 2002
  • 2002-07-25 US US10/522,032 patent/US20050239749A1/en not_active Abandoned
  • 2002-07-25 EP EP02755657A patent/EP1543821B1/en not_active Expired - Lifetime
  • 2002-07-25 EP EP08002241A patent/EP1917956A3/en not_active Withdrawn
  • 2002-07-25 AU AU2002323946A patent/AU2002323946A1/en not_active Abandoned
  • 2002-07-25 AT AT02755657T patent/ATE385769T1/de not_active IP Right Cessation
  • 2002-07-25 DE DE60225077T patent/DE60225077D1/de not_active Expired - Lifetime
  • 2002-07-25 WO PCT/JP2002/007549 patent/WO2004010966A1/ja active IP Right Grant
• 2008
  • 2008-10-24 US US12/257,853 patent/US7763595B2/en not_active Expired - Fee Related
• 2009
  • 2009-10-23 US US12/605,294 patent/US7928090B2/en not_active Expired - Fee Related

Patent Citations (3)

Also Published As

Similar Documents

Legal Events